Markus Reschke
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Immunology top 10%
- Phagocytosis and Immune Regulation
Papers in
-
- Ubiquitin and proteasome pathways 4
- Protein Kinase Regulation and GTPase Signaling 3
- Protein Degradation and Inhibitors 2
- Oncology 14
- Cancer Immunotherapy and Biomarkers 9
- CAR-T cell therapy research 4
- Co-authors
- Axel Ullrich (5 shared papers)Erwin F. Wagner (5 shared papers)Pjotr Knyazev (3 shared papers)Pier Paolo Pandolfi (8 shared papers)Markus Hutterer (2 shared papers)Ingvar Ferby (2 shared papers)Øivind Hvalby (1 shared paper)Vidar R. Jensen (1 shared paper)
- Journals
- Cancer Research (6 papers)Clinical Cancer Research (2 papers)Blood (2 papers)Nature Medicine (2 papers)Journal of Clinical Investigation (2 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Markus Reschke
31 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 93
- Oncology 501
- Immunology 343
- Cancer Research 206
- Hematology 144
- Molecular Biology 872
Countries citing papers authored by Markus Reschke
This map shows the geographic impact of Markus Reschke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Reschke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Reschke more than expected).
Fields of papers citing papers by Markus Reschke
This network shows the impact of papers produced by Markus Reschke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Reschke. The network helps show where Markus Reschke may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Reschke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 311 | |
| 2 | 2008 | 219 | |
| 3 | 2006 | 205 | |
| 4 | 2014 | 146 | |
| 5 | 2008 | 139 | |
| 6 | 2018 | 136 | |
| 7 | 2009 | 84 | |
| 8 | 2005 | 80 | |
| 9 | 2005 | 71 | |
| 10 | 2009 | 64 | |
| 11 | 2015 | 51 | |
| 12 | 2013 | 42 | |
| 13 | 2013 | 36 | |
| 14 | 2013 | 27 | |
| 15 | 2022 | 18 | |
| 16 | 2010 | 15 | |
| 17 | 2020 | 14 | |
| 18 | 2012 | 12 | |
| 19 | 2011 | 12 | |
| 20 | 2018 | 11 |
About Markus Reschke
Markus Reschke is a scholar working on Molecular Biology, Oncology, Immunology, Cancer Research and Pathology and Forensic Medicine, having authored 31 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Ubiquitin and proteasome pathways (4 papers), CAR-T cell therapy research (4 papers), Immunotherapy and Immune Responses (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Acute Myeloid Leukemia Research (3 papers), NF-κB Signaling Pathways (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Oncology (501 citations), Immunology (343 citations), Cancer Research (206 citations), Hematology (144 citations) and Molecular Biology (872 citations). Markus Reschke has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Axel Ullrich, Erwin F. Wagner, Pjotr Knyazev, Pier Paolo Pandolfi, Markus Hutterer, Ingvar Ferby, Øivind Hvalby, Vidar R. Jensen, Rainer Spanagel and Rolf Sprengel. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Blood, Nature Medicine and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.